Aquestive Therapeutics Q1 2024 GAAP EPS $(0.17) Misses $(0.07) Estimate, Sales $12.053M Miss $12.262M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics reported Q1 2024 GAAP EPS of $(0.17), missing estimates by 142.86% and marking a 254.55% decrease from the previous year. Sales were $12.053M, missing estimates by 1.71% but showing an 8.25% increase year-over-year.

May 07, 2024 | 9:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aquestive Therapeutics missed Q1 2024 EPS and sales estimates, with a significant decrease in earnings compared to last year but an increase in sales.
Missing both EPS and sales estimates indicates underperformance, which typically leads to negative investor sentiment and potentially a decrease in stock price in the short term. The significant decrease in earnings compared to the previous year further compounds the negative outlook, despite the slight increase in sales.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100